small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search

Capabilities 83 results

Practice Area

Class Actions & Group Litigation

Winston has developed a consistent record of success handling class action cases in state and federal courts. The practice is anchored by seasoned class action lawyers, many of whom have been recognized by Chambers USA and other ranking organizations as being top practitioners in their field. Our clients rely on us to steer them through class action matters by drawing on the firm’s significant experience in resolving complex litigation using creative and aggressive arguments, across a broad range of class, collective, coordinated, and mass actions, as well multidistrict litigation. We also have succeeded at trial in several class actions—a rare occurrence....Read more

Practice Area

Bankruptcy Litigation & Investigations

Large corporate bankruptcies and companies in financial distress often spawn a complex web of claims by lenders, trustees, debtors, creditors, creditors’ committees, investors, shareholders, and other constituents. Attorneys in Winston & Strawn’s complex commercial litigation group and restructuring and insolvency group—both ranked in Tier 1 by Best Law Firms®—serve as trusted advisors and resolute advocates to protect clients’ business interests and assets in multifaceted Chapter 11 cases and bankruptcy-related disputes. ...Read more

Practice Area

Real Estate

Today’s dynamic commercial real estate market calls for attorneys who bring a broad platform of skills and experience to the table. Our real estate practice offers institutional knowledge across an extensive array of real estate transactions....Read more

Insights & News 2,145 results

Government Program Fraud, False Claims Act & Qui Tam Litigation Playbook

|

May 22, 2025

|

2 Min Read

DOJ announces Civil Rights Fraud Initiative signaling heightened risk of FCA exposure for federal fund recipients based on alleged unlawful discrimination

The U.S. Department of Justice (DOJ) has signaled that it will use the False Claims Act (FCA) as a tool against diversity, equity, and inclusion (DEI) policies that discriminate against certain groups. 

Press Release

|

May 21, 2025

|

1 Min Read

Winston & Strawn Launches Financial Innovation & Regulation Practice

Miami—May 21, 2025—Winston & Strawn LLP is pleased to announce the launch of its Financial Innovation & Regulation Practice (FIR), a strategic response to the rapidly evolving financial services landscape and the increasingly complex legal and regulatory issues that confront companies at the forefront of innovation....Read more

Capital Markets & Securities Law Watch

|

May 20, 2025

|

3 Min Read

Texas Governor Signs Law to Raise the Bar for Shareholder Proposals

The Texas Governor signed a bill that raises the bar for shareholder proposals for Texas corporations. The new law, signed by Governor Abbott on May 19, 2025, has major implications for shareholders of certain Texas corporations and is part of a larger effort to make Texas more business-friendly.

View All Insights & News

Other Results 48 results

Law Glossary

What Is a Class Action?

A class action is a procedural device that allows one or more persons, usually plaintiffs (though federal and state procedural rules also authorize defendant classes) to file suit on behalf of a group of similarly situated persons. Federal law defines a class action as “any civil action filed under Rule 23 of the Federal Rules of Civil Procedure or similar State statute or rule of judicial procedure authorizing an action to be brought by 1 or more representative persons as a class action.”  28 U.S.C. § 1332(d)(1)(B), (d)(8)....Read more

Law Glossary

What Statutes and Regulations Govern the Approval and Marketing of Biosimilars?

Congress passed the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in 2010 an amendment of the Public Health Services Act. The BPCIA is codified at 42 U.S.C. § 262....Read more

Law Glossary

What Exclusivity Periods Are Associated with Biosimilars?

An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)...Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising